Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -6.19% is 74% above its 5-year average of -23.62%, around the middle of its 5-year range (-85.18%–52.35%).
518.68% below its 12-month average of -1.00%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 7.70%.
EBITDA MARGIN
-6.19%
EBITDA MARGIN AVG TTM
-1.00%
EBITDA MARGIN AVG 3Y
-6.63%
EBITDA MARGIN AVG 5Y
-23.62%
EBITDA MARGIN AVG 10Y
-17.74%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-518.68%
CURRENT VS 3Y AVG
+6.60%
CURRENT VS 5Y AVG
+73.80%
CURRENT VS 10Y AVG
+65.11%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Journey Medical Corporation
Market Cap
$177.66M
EBITDA Margin
-6.19%
TTM Avg
-1.00%
3Y Avg
-6.63%
5Y Avg
-23.62%
Market Cap
$175.06M
EBITDA Margin
-6455.53%
TTM Avg
-6455.53%
3Y Avg
-6455.53%
5Y Avg
-6455.53%
Market Cap
$173.99M
EBITDA Margin
-144.16%
TTM Avg
-87.79%
3Y Avg
-115.19%
5Y Avg
-149.65%
Market Cap
$173.23M
EBITDA Margin
-258.92%
TTM Avg
-202.75%
3Y Avg
-649.71%
5Y Avg
-1766.39%
Market Cap
$182.12M
EBITDA Margin
-748.35%
TTM Avg
-748.35%
3Y Avg
-1092.82%
5Y Avg
-1042.94%
Market Cap
$173.18M
EBITDA Margin
-83.89%
TTM Avg
-252.72%
3Y Avg
-1380.70%
5Y Avg
-1383.45%
Market Cap
$171.35M
EBITDA Margin
-18889.15%
TTM Avg
-9445.90%
3Y Avg
-9445.90%
5Y Avg
-9445.90%
Market Cap
$170.98M
EBITDA Margin
-138.09%
TTM Avg
-113.30%
3Y Avg
-81.67%
5Y Avg
-67.39%
Market Cap
$184.71M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Journey Medical Corporation (DERM) | $177.66M | -6.19% | -1.00% | -6.63% | -23.62% |
| Compass Therapeutics, Inc. (CMPX)vs › | $175.06M | -6455.53% | -6455.53% | -6455.53% | -6455.53% |
| Precision BioSciences, Inc. (DTIL)vs › | $173.99M | -144.16% | -87.79% | -115.19% | -149.65% |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.23M | -258.92% | -202.75% | -649.71% | -1766.39% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $182.12M | -748.35% | -748.35% | -1092.82% | -1042.94% |
| Cue Biopharma, Inc. (CUE)vs › | $173.18M | -83.89% | -252.72% | -1380.70% | -1383.45% |
| Nkarta, Inc. (NKTX)vs › | $171.35M | -18889.15% | -9445.90% | -9445.90% | -9445.90% |
| MediWound Ltd. (MDWD)vs › | $170.98M | -138.09% | -113.30% | -81.67% | -67.39% |
| Canton Strategic Holdings Inc (CNTN)vs › | $184.71M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $184.76M | N/A | N/A | N/A | N/A |
Gross Margin
62.2%
EBITDA Margin
-6.2%
Operating Margin
-13.2%
Net Margin
-8.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 7.70% |
| 2026-03-31 | -2.15% |
| 2025-12-31 | 4.01% |
| 2025-09-30 | -2.64% |
| 2025-06-30 | -11.93% |
| 2025-03-31 | -17.03% |
| 2024-12-31 | 23.77% |
| 2024-09-30 | -14.06% |
| 2024-06-30 | -14.06% |
| 2024-03-31 | -71.02% |
| 2023-12-31 | -8.30% |
| 2023-09-30 | 52.35% |
| 2023-06-30 | -38.22% |
| 2023-03-31 | -69.35% |
| 2022-12-31 | -54.79% |
| 2022-09-30 | -52.45% |
| 2022-06-30 | -33.37% |
| 2022-03-31 | 0.65% |
| 2021-12-31 | -48.90% |
| 2021-09-30 | -61.13% |
| 2021-06-30 | -85.18% |
| 2021-03-31 | 10.91% |
| 2020-12-31 | 29.02% |
| 2020-09-30 | 6.30% |
| 2020-06-30 | 20.13% |
| 2020-03-31 | 22.00% |
| 2019-09-30 | -477.14% |
| 2019-06-30 | -24.24% |
| 2019-03-31 | -2551.88% |
| 2018-12-31 | -3135.98% |
| 2018-09-30 | -9054.95% |
| 2018-06-30 | -47.61% |
| 2018-03-31 | -18392.64% |
| 2017-09-30 | -16626.36% |
| 2017-06-30 | -3581.99% |
| 2017-03-31 | -2817.92% |
| 2016-12-31 | -34.95% |
| 2016-09-30 | -21005.04% |
| 2015-12-31 | -417.25% |
